iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/31/2026

1. PCG
2. BRVE
3. OKE
4. SRE
5. CNS
6. ATTO
7. EIX
8. AON
9. HDB
10. XOM

Go back to iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity
IBIO, Inc. (NASDAQ: IBIO) Delayed: 1.36 --0 (-0%)
Previous Close $1.36    52 Week High $0.80 
Open $1.36    52 Week Low $0.34 
Day High $1.36    P/E N/A 
Day Low $1.36    EPS $-0.08 
Volume 351       

IBIO, Inc. (NASDAQ: IBIO) Delayed: 1.36 --0 (-0%)
Previous Close $1.36    52 Week High $0.80 
Open $1.36    52 Week Low $0.34 
Day High $1.36    P/E N/A 
Day Low $1.36    EPS $-0.08 
Volume 351